• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Tivic Announces Appointment of New Interim CFO, Kimberly Bambach, and Strategic Advisor to the Board, Christine Valauri

    5/1/23 9:30:00 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $TIVC alert in real time by email

    Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the appointment of veteran Kimberly Bambach to serve as Interim Chief Financial Officer of the company and the engagement of Christina Valauri as a strategic advisor to the Board of Directors. These additions aim to strengthen the company's financial foundation and bring growth and M&A expertise to the team.

    Ms. Bambach brings over 30 years of financial leadership experience in both public and private companies across industries. Her background includes financial leadership in medical and retail markets, manufacturing, wholesale distribution, licensing, digital media, and broadcasting. Bambach most recently served as Chief Financial Officer of Jushi Holdings Inc., where she played a pivotal role in the company's rapid growth driving over a dozen acquisitions in a complex regulatory environment. Since leaving Jushi as CFO, Bambach has continued as an advisor to the company while providing consulting services to several private companies. Before Jushi, Ms. Bambach held executive leadership and finance positions in both public and private equity companies. She replaces Veronica Cai, who served as Chief Financial Officer of the Company since April 2022. Ms. Bambach holds a BA from SUNY Brockport and an MBA from Pace University.

    "I am pleased to have such an experienced financial leader join our leadership team," said Jennifer Ernst, CEO of Tivic. "As we prepare Tivic for the future in a rapidly evolving health tech market, I am confident that Kimberly's strong leadership and expertise in financial and operational improvements will have an immediate positive impact on our company."

    Ms. Valauri will serve as a strategic advisor to Tivic's board of directors. She brings a 30 year proven track record as a senior healthcare analyst, including leadership roles as US and Global Head of Equity Research and Managing Director at Cantor Fitzgerald. Ms. Valauri is the founding partner and CEO of Sagestone Advisory, LLC and a partner of NextGen Venture Partners, an early stage venture capital firm with a network of 1600 proven entrepreneurs and accomplished professionals. Her background in equity securities research has provided a deep base of experience in pharmaceutical, biotech, and med-tech companies. She has extensive experience identifying and analyzing the commercial potential of breakthrough innovations, as well as mentoring and advising the C-suite teams of private and public early-stage healthcare companies through product development, regulatory, go-to-market strategies, potential mergers and acquisitions, and IPOs. She has successfully developed and executed transformational business strategies to drive growth and enhance operating performance.

    Ms. Valauri has previously held senior roles at US and international firms including ING, Credit Lyonnais (acquired by Credit Agricole), Natixis, and was the Global Director of Research for Cantor Fitzgerald. She has been recognized by The Wall Street Journal's "Best on The Street" All Star Analyst Survey and has received the Award for Excellence - Medical Education Public Affairs Association of American - Medical Colleges - New York University. She currently serves as a senior advisor with Hanover International, Inc., Astia.org, and as a mentor and advisor at the Weill Cornell Medicine BioVenture eLab. Ms. Valauri earned her BA in Biology from Reed College and MBA from Cornell University.

    "The Board and I value the astute insight and understanding of emerging growth companies Christina is bringing to this board advisory role," said Jennifer Ernst, CEO of Tivic. "Christina is a seasoned financial steward and her expertise will be invaluable to our evaluation of transformational growth opportunities through internal development, strategic partnerships and M&A to drive value for our shareholders and customers."

    About Tivic

    Tivic is a commercial health tech company advancing the field of bioelectronic medicine. Tivic's patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures. Tivic's non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic's first commercial product ClearUP is an FDA approved, award-winning, handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and is available through online retailers and commercial distributors. For more information visit http://tivichealth.com @TivicHealth

    Forward-Looking Statements

    This press release may contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Tivic's actual results to differ from those contained in the forward-looking statements, see Tivic's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 31, 2023, under the heading "Risk Factors"; as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230501005317/en/

    Get the next $TIVC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TIVC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TIVC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Operating Officer Handley Michael K

      4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

      2/24/25 5:01:03 PM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 3 filed by new insider Handley Michael K

      3 - Tivic Health Systems, Inc. (0001787740) (Issuer)

      2/24/25 5:00:08 PM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Director Valauri Christina Rizopoulos

      4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

      12/20/24 5:15:03 PM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TIVC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tivic Shareholders Approve Key Proposals in Support of Strategic Transformation; Lisa Wolf Appointed Permanent CFO

      Company provides additional management updates Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that key proposals needed to carry out the company's strategic transformation were approved by shareholders at its annual meeting held on June 30, 2025. The approved proposals included the issuance of equity as a form of payment pursuant to Tivic's worldwide exclusive license agreement for Entolimod™ and Entolasta™, including for uses in acute radiation syndrome, neutropenia and other indications in oncology and hematology. Shareholders also approved the Company's issuance of equity in accordance with previously announced financing arrangeme

      7/8/25 8:30:00 AM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Tivic Health Completes Optimization Study for Its Non-Invasive Vagus Nerve Stimulation Device

      Breakthrough Findings to be Reported Later this Year and Applied to Upcoming Phase I Clinical Trial Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company developing treatments that stimulate immune pathways to treat disease, today announced it has completed all study visits in the Optimization Study for its patent pending, non-invasive cervical vagus nerve stimulation (ncVNS) device. Initial findings reinforce the importance of personalization for therapeutic efficacy. Tivic expects to release the study results later this year. The study was conducted by The Feinstein Institute of Bioelectronic Medicine with the objective of identifying device parameters th

      6/25/25 8:30:00 AM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Tivic Health Announces 2025 Annual Meeting of Stockholders

      Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today its Virtual Annual General Meeting of Shareholders will be held on Monday, June 30, 2025 at 1:00 PM, Pacific Time | 4:00 PM Eastern Time. The Company has adopted a virtual format for its Annual Meeting to provide a consistent and convenient experience for all stockholders regardless of their location. In lieu of a live Q&A session, stockholders can submit questions for management's consideration through the virtual Annual Meeting platform both before and during the Annual Meeting. WHEN: Monday, June 30, 2025 TIME: 1:00 PM PT | 4:00 PM ET WHERE: w

      6/24/25 8:30:00 AM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TIVC
    SEC Filings

    See more
    • Tivic Health Systems Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

      7/7/25 4:11:16 PM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Tivic Health Systems Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

      6/25/25 4:31:27 PM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Tivic Health Systems Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

      6/25/25 8:30:41 AM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TIVC
    Leadership Updates

    Live Leadership Updates

    See more
    • Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team

      Handley Joins as President of Tivic Biopharma and Chief Operating Officer of Tivic Health Following Its Licensing of Strategic Biopharma Assets From Statera Biopharma Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today that Michael K. Handley, formerly Chief Executive Officer, President and Chairman of Statera Biopharma, Inc., has joined Tivic Health as the President of Tivic Biopharma, a newly formed division of Tivic Health. Additionally, he will assume the role of Chief Operating Officer of Tivic Health and will work closely with the CEO and other leadership team members to develop and operationalize company-wide strategies. His key responsi

      2/24/25 8:15:00 AM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Tivic Health Appoints Lisa Wolf as Interim Chief Financial Officer

      Kimberly Bambach, Ms. Wolf's predecessor, continues with Tivic as advisor focused on strategic transactions and special projects Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to announce the appointment of Lisa Wolf as Interim Chief Financial Officer (CFO) of the company, effective October 1, 2024. Ms. Wolf will take over from Kimberly Bambach, who has served as the company's interim CFO since April 2023. Ms. Bambach will continue with Tivic in an advisory role for strategic transactions and other special projects. "Lisa has served as a senior member of Tivic's finance team for over two

      9/13/24 5:29:00 PM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Tivic Announces Appointment of New Interim CFO, Kimberly Bambach, and Strategic Advisor to the Board, Christine Valauri

      Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the appointment of veteran Kimberly Bambach to serve as Interim Chief Financial Officer of the company and the engagement of Christina Valauri as a strategic advisor to the Board of Directors. These additions aim to strengthen the company's financial foundation and bring growth and M&A expertise to the team. Ms. Bambach brings over 30 years of financial leadership experience in both public and private companies across industries. Her background includes financial leadership in medical and retail markets, manufacturing, wholesale distrib

      5/1/23 9:30:00 AM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TIVC
    Financials

    Live finance-specific insights

    See more
    • Tivic Reports First Quarter 2025 Financial Results and Provides Updates on Business Transformation

      Pre-recorded Conference Call to Follow at 1:30 p.m. PDT/4:30 p.m. EDT Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced financial results for the first quarter ended March 31, 2025 and outlined operational highlights based on its newly expanded clinical pipeline. "This is a defining time for the company. During the quarter we initiated a significant strategic shift, dramatically expanding Tivic's clinical pipeline for restoring immune system health," stated Tivic CEO Jennifer Ernst. "In February, we executed a comprehensive worldwide exclusive licensing agreement for the Phase III TLR5 agonist, Entolimod and its molecular derivative, Ent

      5/15/25 4:05:00 PM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Tivic Health to Report First Quarter 2025 Financial Results on May 15th Via Conference Call and Webcast

      Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, today announced that it will report its first quarter results for 2025 via pre-recorded conference call and webcast on Thursday, May 15, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 1-877-407-0779 International: 1-201-389-0914 Conference ID: 13753498 Webcast Link https://viavid.webcasts.com/starthere.jsp?ei=1717125&tp_key=322c3ca4f6 About Tivic Health Systems, Inc. Tivic Health is a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight

      5/9/25 8:30:00 AM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Tivic Reports Year End 2024 Financial Results and Provides Overview of Strategy for Transformation and Growth

      Pre-recorded Conference Call and Webcast to Follow Today at 1:30 PM PDT / 4:30 PM EDT Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, today announced year end December 31, 2024 financial results, highlighted key developments in its clinical program expansion and discussed progress made across the company's operations. "The important strategic events of the past several months have been nothing short of transformative," stated Tivic Health Chief Executive Officer, Jennifer Ernst. "We have successfully reshaped the company by expanding Tivic's opportunities in the biotech sector by in-licensing a late-stage biologic immunotherapy and advancing our ongoing work

      3/21/25 4:00:00 PM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TIVC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Tivic Health Systems Inc.

      SC 13G - Tivic Health Systems, Inc. (0001787740) (Subject)

      5/15/24 4:47:23 PM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Tivic Health Systems Inc. (Amendment)

      SC 13G/A - Tivic Health Systems, Inc. (0001787740) (Subject)

      2/9/24 4:05:08 PM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Tivic Health Systems Inc. (Amendment)

      SC 13G/A - Tivic Health Systems, Inc. (0001787740) (Subject)

      2/1/24 9:01:29 AM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care